The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG

Translational research in Huntington’s disease: opening up for disease modifying treatment

(2013) Jean-Marc Burgunder   Translational Neurodegeneration

Sativex-like Combination of Phytocannabinoids is Neuroprotective in Malonate-Lesioned Rats, an Inflammatory Model of Huntington’s Disease: Role of CB1 and CB2 Receptors

(2012) Sara Valdeolivas et al.   ACS Chemical Neuroscience

Discovery of Prostamide F2α and Its Role in Inflammatory Pain and Dorsal Horn Nociceptive Neuron Hyperexcitability

(2012) Luisa Gatta et al.   PLoS One

A Dysregulated Endocannabinoid-Eicosanoid Network Supports Pathogenesis in a Mouse Model of Alzheimer's Disease

(2012) Justin R. Piro et al.   Cell Reports

Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-γ

(2011) Huizhi Du et al.   BRITISH JOURNAL OF PHARMACOLOGY

Prospects for cannabinoid therapies in basal ganglia disorders

(2011) Javier Fernández-Ruiz et al.   BRITISH JOURNAL OF PHARMACOLOGY

Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease

(2011) Onintza Sagredo et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Endocannabinoid Hydrolysis Generates Brain Prostaglandins That Promote Neuroinflammation

(2011) D. K. Nomura et al.   SCIENCE

Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity

(2009) Javier Palazuelos et al.   BRAIN

Cannabinoid CB2receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease

(2009) Onintza Sagredo et al.   GLIA

Cannabinoid activation of peroxisome proliferator-activated receptors: Potential for modulation of inflammatory disease

(2009) S.E. O'Sullivan et al.   IMMUNOBIOLOGY

Prostaglandin E2 glycerol ester, an endogenous COX-2 metabolite of 2-arachidonoylglycerol, induces hyperalgesia and modulates NFκB activity

(2008) S Shu-Jung Hu et al.   BRITISH JOURNAL OF PHARMACOLOGY

The Endocannabinoid System in Huntingtons Disease

(2008) M. Pazos et al.   CURRENT PHARMACEUTICAL DESIGN

Cyclooxygenase-1 and -2 in the Different Stages of Alzheimers Disease Pathology

(2008) J. Hoozemans et al.   CURRENT PHARMACEUTICAL DESIGN

Cyclooxygenase-2 in Synaptic Signaling

(2008) Hongwei Yang et al.   CURRENT PHARMACEUTICAL DESIGN

2-Arachidonoylglycerol elicits neuroprotective effects on excitotoxically lesioned dentate gyrus granule cells via abnormal-cannabidiol-sensitive receptors on microglial cells

(2008) Susanne Kreutz et al.   GLIA

Endocannabinoid 2-Arachidonoylglycerol Protects Neurons by Limiting COX-2 Elevation

(2008) Jian Zhang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Tetrahydrolipstatin Analogues as Modulators of Endocannabinoid 2-Arachidonoylglycerol Metabolism

(2008) Giorgio Ortar et al.   JOURNAL OF MEDICINAL CHEMISTRY

Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects

(2008) Jonathan Z Long et al.   Nature Chemical Biology

The pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 products

(2008) D.F. Woodward et al.   PHARMACOLOGY & THERAPEUTICS

Peroxisome Proliferator-Activated Receptors: “Key” Regulators of Neuroinflammation after Traumatic Brain Injury

(2008) Philip F. Stahel et al.   PPAR Research

Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease

(2007) Tiziana Bisogno et al.   NEUROCHEMISTRY INTERNATIONAL